Evidence map›Paper›PMID 27483449›Full record

ArticleArthritis & rheumatology (Hoboken, N.J.)2017

Differences in the Spectrum of Anti-Citrullinated Protein Antibody Fine Specificities Between Malaysian and Swedish Patients With Rheumatoid Arthritis: Implications for Disease Pathogenesis.

Chun Lai Too, Shahnaz Murad, Monika Hansson, Linda Mathsson Alm, Jasbir Singh Dhaliwal, Rikard Holmdahl, Per-Johan Jakobsson, Lars Alfredsson, Lars Klareskog, Johan Rönnelid and 1 more

Open access · hybridAbstract readComparative Study
In one paragraph

Article in Arthritis & rheumatology (Hoboken, N.J.), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 2 pooled it
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 2 syntheses or guidelines pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 7 institutions in 3 countries.

Chun Lai TooInstitute for Medical Research, Kuala Lumpur, Malaysia, and Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.
Shahnaz MuradMinistry of Health, Putrajaya, Malaysia.
Monika HanssonKarolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.
Linda Mathsson AlmUppsala University and Thermo Fisher Scientific, Uppsala, Sweden.
Jasbir Singh DhaliwalInstitute for Medical Research, Kuala Lumpur, Malaysia.
Rikard HolmdahlKarolinska Institutet, Stockholm, Sweden, and Southern Medical University, Guangzhou, China.
Per-Johan JakobssonKarolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.
Lars AlfredssonKarolinska Institutet and Center for Occupational and Environmental Medicine, Stockholm, Sweden.
Lars KlareskogKarolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.
Johan RönnelidUppsala University, Uppsala, Sweden.
Leonid PadyukovKarolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.
Karolinska Institutet · SEInstitute for Medical Research · MYKarolinska University Hospital · SEMinistry of Health · MYSouthern Medical University · CNThermo Fisher Scientific (Sweden) · SEUppsala University · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveAntibodies to the citrullinated protein antigens (ACPAs) are important in the diagnosis and pathogenesis of rheumatoid arthritis (RA). However, the prevalence of ACPAs with different fine specificities in different populations is unclear. This study sought to examine the fine specificity of the antibody responses toward citrullinated proteins in RA patients from Malaysia, an area where genetic and environmental determinants of RA are different from those in more frequently studied cohorts of Caucasian subjects.

methodsA multiplex analytic microarray system was used to analyze the occurrence of antibodies to 10 different citrullinated peptides (filaggrin [fil307-324], vimentin [Vim2-17, Vim60-75], fibrinogen [Fibα563-583, Fibα580-600, Fibβ36-52, Fibβ62-81a, Fibβ62-81b], enolase [Eno5-21], and type II collagen [CitCII355-378]) in serum samples from 4,089 RA patients (1,231 Malaysian and 2,858 Swedish) and 827 healthy control subjects (249 Malaysian and 578 Swedish). The positive reaction threshold for each peptide was set separately for each population based on a specificity of 98%.

resultsDistinct differences in the frequencies of 5 ACPA fine specificities (Vim60-75, Vim2-17, Fibβ62-81b, Eno5-21, and CitCII355-378) were found between the Malaysian and Swedish RA populations, despite a nearly identical percentage of patients in each population who were positive for anti-cyclic citrullinated peptide 2 antibodies. In Malaysian RA patients compared with Swedish RA patients, the frequencies of antibodies to Vim60-75 (54% versus 44%, corrected P [P

conclusionSerum ACPA fine specificities differ between RA patients in different populations, although the total proportions of individuals positive for ACPAs are similar. Differing patterns of ACPA fine specificity could be attributed to variations in genetic and/or environmental factors.

Indexed as

Antibody SpecificityAdolescentAdultAgedArthritis, RheumatoidAutoantibodiesCase-Control StudiesFemaleFilaggrin ProteinsHumansMalaysiaMaleMiddle AgedPeptides, CyclicSwedenYoung AdultAutoantibodiescyclic citrullinated peptideFilaggrin ProteinsFLG protein, humanPeptides, Cyclic

Identifiers

PMID27483449
PMCPMC6681166
OpenAlexW2559724410

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.